After finishing at $122.83 in the prior trading day, Merck & Co Inc (NYSE: MRK) closed at $123.75, up 0.75%. In other words, the price has increased by $+0.92 from its previous closing price. On the day, 8249561 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of MRK by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 43.77 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.28. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.25. In the meantime, Its Debt-to-Equity ratio is 0.97 whereas as Long-Term Debt/Eq ratio is at 0.92.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, TD Cowen on January 04, 2024, Upgraded its rating to Outperform and sets its target price to $135 from $125 previously.
On November 09, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $115.
BMO Capital Markets Upgraded its Market Perform to Outperform on October 27, 2023, while the target price for the stock was maintained at $132.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 14 ’24 when Davis Robert M sold 85,021 shares for $125.40 per share. The transaction valued at 10,661,574 led to the insider holds 348,327 shares of the business.
Litchfield Caroline sold 38,291 shares of MRK for $4,805,520 on Feb 14 ’24. The EVP & CFO now owns 50,908 shares after completing the transaction at $125.50 per share. On Feb 13 ’24, another insider, Davis Robert M, who serves as the Chairman, CEO & President of the company, sold 150,000 shares for $125.85 each. As a result, the insider received 18,877,424 and left with 348,327 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRK now has a Market Capitalization of 313.41B and an Enterprise Value of 341.38B. As of this moment, Merck’s Price-to-Earnings (P/E) ratio for their current fiscal year is 936.08, and their Forward P/E ratio for the next fiscal year is 12.69. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 13.89. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.23 while its Price-to-Book (P/B) ratio in mrq is 8.34. Its current Enterprise Value per Revenue stands at 5.68 whereas that against EBITDA is 49.42.
Stock Price History:
Over the past 52 weeks, MRK has reached a high of $130.24, while it has fallen to a 52-week low of $99.14. The 50-Day Moving Average of the stock is 121.12, while the 200-Day Moving Average is calculated to be 110.46.
Shares Statistics:
The stock has traded on average 8.04M shares per day over the past 3-months and 7.04M shares per day over the last 10 days, according to various share statistics. A total of 2.53B shares are outstanding, with a floating share count of 2.53B. Insiders hold about 0.15% of the company’s shares, while institutions hold 78.68% stake in the company. Shares short for MRK as of Feb 15, 2024 were 16.82M with a Short Ratio of 2.09, compared to 20.81M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.66% and a Short% of Float of 0.66%.
Dividends & Splits
In the trailing 12 months, MRK’s forward annual dividend rate was 2.92, compared to 2.96 this year. Against a Trailing Annual Dividend Yield of 2.38%, it implies a Forward Annual Dividend Yield of 2.49%. The stock’s 5-year Average Dividend Yield is 2.90. The current Payout Ratio is 2065.60% for MRK, which recently paid a dividend on Apr 05, 2024 with an ex-dividend date of Mar 14, 2024. Stock splits for the company last occurred on Jun 03, 2021 when the company split stock in a 1048:1000 ratio.
Earnings Estimates
Its stock is currently analyzed by 15 different market analysts. On average, analysts expect EPS of $2.06 for the current quarter, with a high estimate of $2.24 and a low estimate of $1.78, while EPS last year was $1.4. The consensus estimate for the next quarter is $2.02, with high estimates of $2.35 and low estimates of $1.84.
Analysts are recommending an EPS of between $8.91 and $8.44 for the fiscal current year, implying an average EPS of $8.57. EPS for the following year is $9.76, with 21 analysts recommending between $10.44 and $9.12.
Revenue Estimates
12 analysts predict $15.12B in revenue for the current quarter. It ranges from a high estimate of $15.67B to a low estimate of $14.87B. As of the current estimate, Merck & Co Inc’s year-ago sales were $13.78B, an estimated increase of 9.70% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $15.84B, an increase of 5.30% less than the figure of $9.70% in the same quarter last year. There is a high estimate of $16.1B for the next quarter, whereas the lowest estimate is $15.31B.
A total of 21 analysts have provided revenue estimates for MRK’s current fiscal year. The highest revenue estimate was $64.97B, while the lowest revenue estimate was $62.6B, resulting in an average revenue estimate of $63.82B. In the same quarter a year ago, actual revenue was $60.12B, up 6.20% from the average estimate. Based on 20 analysts’ estimates, the company’s revenue will be $67.91B in the next fiscal year. The high estimate is $70.13B and the low estimate is $66.08B. The average revenue growth estimate for next year is up 6.40% from the average revenue estimate for this year.
